Skip to main content

Tweets

2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/PPAHocDWBj https://t.co/hZDGOF6r9k
Dr. John Cush @RheumNow ( View Tweet )
3 days 1 hour ago
Five Senses of Medicine - nice graphic download on Clinical Skils (from Annals of Internal Medicine) https://t.co/8RNpqovtVP https://t.co/FkOSZCtv8c
Dr. John Cush @RheumNow ( View Tweet )
3 days 2 hours ago
Efficacy and Safety of JAK Inhibitors in Psoriatic Disease There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe PSO and PsA, according to a systematic review in BMC Rheumatology.https://t.co/8Y4V1jUlzo https://t.co/eFqknUfGat
Dr. John Cush @RheumNow ( View Tweet )
3 days 19 hours ago
Study of 67 OA TKR pts looked for CPPD - defined as "appears as linear/punctate opacities w/in cartilage, synovium, Jt capsule or tendons/entheses". Xrays had specificity of 92%, sensitivity 54%, PPV 88%, NPV 66% (needs to be distinguished from BCP) https://t.co/i0ZagblzPZ https://t.co/CiusWPzjrK
Dr. John Cush @RheumNow ( View Tweet )
3 days 21 hours ago
Are We Overcautious With TNF Inhibitors in Pregnancy? What may seem like a prudent approach to treatment of IBD in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from TNF inhibitors.https://t.co/gYqJDBHTBQ https://t.co/aBXl49wJzM
Dr. John Cush @RheumNow ( View Tweet )
4 days ago
Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/ZJsR0R5WNW https://t.co/2GU5aaSwDZ
Dr. John Cush @RheumNow ( View Tweet )
4 days 1 hour ago
IL-18 is a proinflammatory cytokine involved in innate &adaptive immune responses. IL-18 is a key mediator in autoinflammatory diseases, MAS, Still’s disease. Serum IL-18 levels may be useful in diagnosis and monitoring of disease activity https://t.co/P8ecLAtNx5 https://t.co/3mo1vcYKUr
Dr. John Cush @RheumNow ( View Tweet )
4 days 21 hours ago
Cancer Risk with Scleroderma Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer.https://t.co/2sCI6AejRn https://t.co/estX9D39tZ
Dr. John Cush @RheumNow ( View Tweet )
4 days 23 hours ago
Is PMR the Next Indication for Tocilizumab? About half of patients with steroid-dependent PMR were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, a randomized phase III trial showed. https://t.co/fe8d6LNMOh https://t.co/RLhnaEPOVK
Dr. John Cush @RheumNow ( View Tweet )
5 days 1 hour ago
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.https://t.co/8hICpPVC8b https://t.co/GDHaBb6fFC
Dr. John Cush @RheumNow ( View Tweet )
5 days 2 hours ago
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO Sponsored by Lilly USA Listen to Drs Mease and Armstrong discuss a multidisciplinary approach and important considerations when treating patients with joint and skin concerns. https://t.co/ZAVA83QNa3

Dr. John Cush @RheumNow ( View Tweet )

5 days 19 hours ago
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/JtaBxVjoak https://t.co/k34P6SjC6L
Dr. John Cush @RheumNow ( View Tweet )
5 days 20 hours ago
×